Pfizer says Canada just approved its new COVID-19 vaccine for this fall
In a news release, Pfizer Canada and BioNTech said that Health Canada authorized the LP.8.1 variant COVID-19 vaccine for individuals six months and older.
The updated vaccine targets the Omicron LP.8.1 variant of COVID-19.
The company said the vaccine will be available in most pharmacies across the country in the fall, noting each province has different eligibility criteria for its public vaccination program.
Provincial and territorial health authorities will share more details about rollouts.
1:47
COVID vaccine concerns from vulnerable Albertans
Most provinces and territories in Canada do not charge Canadians for the COVID-19 vaccine, however Alberta recently changed its own strategy, requiring residents who want it this year to pre-order the shot and pay for it out of their own pocket.
Story continues below advertisement
The cost is not yet known.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
The change took effect last week but was first announced in June after the federal government put the provinces in charge of buying COVID-19 vaccines, as is routine with other immunization programs.
Alberta is also making the vaccine only available through a public health clinic and not a pharmacy.
The cost of vaccinations will be covered for seniors in care homes or receiving home care, those with compromised immune systems and people on social programs.
Pfizer said the approval of the vaccine by Health Canada is 'based on the cumulative body of evidence previously submitted by Pfizer and BioNTech,' including clinical, non-clinical and real-world data.
Global News has reached out to Health Canada about the approval and what vaccines have been approved related to targeting the LP.8.1 variant and when they'll be made available to provinces for use.
— With files from Global News' Ken MacGillivray and Meghan Cobb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
3 hours ago
- Toronto Star
Alberta government to cover COVID-19 shots for health-care workers in policy reversal
EDMONTON - In a partial policy reversal, Alberta's government said Tuesday it will cover the cost of COVID-19 vaccinations for health-care workers. Maddison McKee, spokesperson to Primary and Preventative Health Services Minister Adriana LaGrange, said in an email that COVID-19 vaccine coverage will be extended to all health-care workers this fall under the first phase of the province's vaccination rollout.
Winnipeg Free Press
3 hours ago
- Winnipeg Free Press
CP NewsAlert: Alberta to pay for COVID shots for health workers in policy reversal
EDMONTON – Alberta's government says it will cover the cost of COVID-19 vaccinations for health-care workers in a partial policy reversal. It comes two months after the government said most Albertans, including health workers, would have to pay for COVID-19 shots this fall. Public health experts and health-care unions called it irresponsible to force front-line workers to pay for protection in the workplace. Premier Danielle Smith has said the aim of the new policy is to prevent wastage, after some $135 million was spent on unused doses. The government hasn't finalized how much other Albertans will need to pay, but an estimated cost to buy each shot is $110. The province says those who have compromised immune systems, people on social programs and seniors in congregate settings will be covered. More coming.
CBC
3 hours ago
- CBC
Ozempic approved in Canada to slow kidney decline, prevent cardiovascular disease
Social Sharing Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Avoiding dialysis Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. "What my patients are scared of is dialysis — dialysis or a transplant," said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. "I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of." WATCH | Retinal disease tied to Ozempic and Mounjaro use in people with diabetes: Ozempic, Mounjaro linked to vision loss in diabetics 2 months ago Researchers at the University of Toronto have found GLP-1 weight loss and diabetes drugs like Ozempic and Mounjaro double the risk of a severe form of vision loss among diabetics, affecting daily activities such as reading and driving. Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is "great news." "The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool," said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication in 2018 because it reduces blood sugar. Semaglutide can also decrease appetite. In 2021, Health Canada approved it as a weight-loss drug for people with obesity at a higher dose sold by Novo Nordisk under the brand name Wegovy. Following global supply shortages, in January 2025 Health Canada said the supply of Ozempic and other GLP-1 receptor agonists had stabilized. Heart protection benefits established In an email to The Canadian Press, Health Canada confirmed that on Aug. 13, it had approved Ozempic "to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease." Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. "The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people [with Type 2 diabetes]. That's a very exciting combination," he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said.
